DE602005007245D1 - - Google Patents

Info

Publication number
DE602005007245D1
DE602005007245D1 DE602005007245T DE602005007245T DE602005007245D1 DE 602005007245 D1 DE602005007245 D1 DE 602005007245D1 DE 602005007245 T DE602005007245 T DE 602005007245T DE 602005007245 T DE602005007245 T DE 602005007245T DE 602005007245 D1 DE602005007245 D1 DE 602005007245D1
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005007245T
Other languages
German (de)
Inventor
Andrew W Stamford
Ying Huang
Guoqing Li
Corey O Strickland
Johannes H Voigt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602005007245D1 publication Critical patent/DE602005007245D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602005007245T 2004-07-28 2005-07-26 Expired - Lifetime DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189904P 2004-07-28 2004-07-28
PCT/US2005/026468 WO2006014944A1 (en) 2004-07-28 2005-07-26 Macrocyclic beta-secretase inhibitors

Publications (1)

Publication Number Publication Date
DE602005007245D1 true DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-07-10

Family

ID=35106859

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005007245T Expired - Lifetime DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-07-28 2005-07-26

Country Status (12)

Country Link
US (2) US7652003B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1781644B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2008508289A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101027297B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR050184A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE396990T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2575340A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2306200T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007001102A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI297337B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006014944A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
EP1851208A1 (en) * 2005-01-13 2007-11-07 Novartis AG Macrocyclic compounds useful as bace inhibitors
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
AR054620A1 (es) * 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
JP2009539983A (ja) 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
AU2007275132A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
ATE549923T1 (de) 2006-10-06 2012-04-15 Merck Sharp & Dohme Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
CA2704698A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
CA2747744A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
AU2009330234A1 (en) 2008-12-22 2011-07-07 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
KR102160388B1 (ko) 2012-03-19 2020-09-28 버크 인스티튜트 포 리서치 온 에이징 App 특이적 bace 억제제(asbi) 및 이의 용도
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2956443B1 (en) 2013-02-12 2019-09-25 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN105175488A (zh) * 2015-09-07 2015-12-23 西北农林科技大学 一种具有抗老年痴呆症活性的化合物及其制备方法
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500772A (ja) 1987-10-21 1991-02-21 ジ・アップジョン・カンパニー (1‐アミノ‐2‐ヒドロキシ‐2‐ヘテロサイクリック)エチル基を含有するレニン抑制物質類
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
WO2002002518A2 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
US6969709B2 (en) * 2001-06-12 2005-11-29 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
DE60329316D1 (de) * 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
US7371853B2 (en) * 2003-01-07 2008-05-13 Merck & Co., Inc. Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease
WO2006009653A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
PE20060299A1 (es) 2004-06-16 2006-05-18 Wyeth Corp DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP2009500329A (ja) 2005-06-30 2009-01-08 ワイス アミノ−5−(6員)ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
PE20070461A1 (es) 2005-09-26 2007-05-10 Wyeth Corp Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona como inhibidores de b-secretasa
WO2007114771A1 (en) 2006-04-05 2007-10-11 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
US20060040948A1 (en) 2006-02-23
CN101027297B (zh) 2010-09-08
AR050184A1 (es) 2006-10-04
TW200607807A (en) 2006-03-01
JP2008508289A (ja) 2008-03-21
ATE396990T1 (de) 2008-06-15
US8012953B2 (en) 2011-09-06
US7652003B2 (en) 2010-01-26
TWI297337B (en) 2008-06-01
CA2575340A1 (en) 2006-02-09
ES2306200T3 (es) 2008-11-01
HK1102328A1 (en) 2007-11-16
CN101027297A (zh) 2007-08-29
WO2006014944A1 (en) 2006-02-09
EP1781644B1 (en) 2008-05-28
MX2007001102A (es) 2007-04-13
EP1781644A1 (en) 2007-05-09
US20100178294A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
BE2024C508I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2022C549I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2023C542I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2021C001I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C513I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C517I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C540I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C523I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C548I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C506I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2018C045I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2020C525I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C063I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C027I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2017C002I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C067I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2016C014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C041I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C038I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2015C066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE2019C535I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2005270017A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE602005007245D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition